@article { author = {}, title = {Immunohistochemical (IHC) HER-2/neu and Fluorescent-In–Situ Hybridization (FISH) Gene Amplification of Breast Cancer in Indian Women}, journal = {Asian Pacific Journal of Cancer Prevention}, volume = {12}, number = {1}, pages = {179-183}, year = {2011}, publisher = {West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.}, issn = {1513-7368}, eissn = {2476-762X}, doi = {}, abstract = {Background: The concordance rate between immunohistochemical (IHC) and fluorescence in situ hybridization(FISH) results for HER2/neu according to clinical performance is controversial. The present prospective studywas theerefore conducted in Indian breast cancer patients. Methods: Fifty cases (n=50) of invasive duct cancerof breast tested for HER-2/neu by IHC and scored as 0, 1+, 2+ and 3+ by pathologists were further analyzed byFISH using a commercially available double-color probe, and the findings compared. Results: A total concordanceof 82.0% was observed with a Kappa coefficient of 0.640 (P < 0.001). A high discordance was observed in 30.0%of the patients with IHC 2+, 7.1% in IHC 3+, 19.2% overall in IHC 0 and 1+. Conclusion: IHC can be usedfirstly to screen the HER-2/neu status, and FISH can be used as a supplementary role to IHC and 2+ and somenegative cases. And only those cases with HER-2/neu status of IHC 3+ or FISH positive should be treated withHerceptin (Trastuzumab).}, keywords = {breast cancer,HER-2/neu,fish,IHC,Herceptin (Trastuzumab)}, url = {https://journal.waocp.org/article_25493.html}, eprint = {https://journal.waocp.org/article_25493_6b289a129a35c972aaca5eca5380260d.pdf} }